Can 'Zombie Cell' cleaners fight Alzheimer's? new trial tests idea
NCT ID NCT04685590
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing whether a combination of two drugs, dasatinib and quercetin, is safe and feasible for people with early-stage Alzheimer's or mild cognitive impairment. The drugs aim to clear aging 'senescent' cells that may contribute to brain damage. 48 participants aged 60 and older are receiving either the drug combo or a placebo for 12 weeks, with follow-up for up to 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dasatinib and Quercetin (a drug combination that targets aging cells)
What this could lead to
If it works, this could point toward a new way to slow or stop early Alzheimer's by clearing aging cells from the brain.
What could go wrong
This is a small, early-phase trial focused on safety, not proof of effectiveness. The treatment may not improve symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
FISEVI Clinical Site
Seville, Spain
-
Fundación ACE Clinical Site
Barcelona, Spain
-
Hospital Clínic de Barcelona Site
Barcelona, Spain
-
Sant Pau Clinical Site
Barcelona, Spain
-
Wake Forest Health Sciences
Winston-Salem, North Carolina, 27157, United States